Navigation Links
Shield Therapeutics Completes Recruitment to Pivotal Phase 3 Programme for Treatment of Iron Deficiency
Date:6/23/2013

LONDON, June 24, 2013 /PRNewswire/ --

Shield Therapeutics, the independent specialty mineral medicines pharmaceutical company, today announces that it has completed recruitment of patients into its pivotal Phase 3 programme of ST10 for the treatment of iron-deficient anaemia.  ST10 is a novel form of ferric iron taken orally.

Patients with inflammatory bowel disease and anaemia have been recruited and randomised when oral ferrous products have been ineffective due to intolerance and/or inadequate therapeutic benefit.  The primary endpoint of this pivotal international, multi-centre programme is haemoglobin change after 12 weeks' treatment with ST10 compared to placebo.  Subjects have been included from expert centres in Austria, Germany, Hungary and the UK and either randomised to receive 30mg of ST10 twice a day, or a matched placebo capsule.  Following the randomised treatment period there is an open-label phase that allows all patients to be treated with ST10 for an additional year.  Other iron therapies have not been permitted during the study.  

Shield Therapeutics expects to report top-line results from the study at the end of Q4 2013 and anticipates these results will provide confirmatory pivotal clinical data that may form the basis of an MAA submission to the European regulatory authorities in 2014.  The data is also expected to form part of a subsequent NDA submission in the USA.

Commenting on the study, Professor Gasche, Professor of Medicine, Medical University of Vienna, Austria said:

"Inflammatory bowel disease is one of the most prevalent diseases managed by gastroenterologists.  Approximately half of all IBD patients develop iron deficiency and that can readily progress to more severe anaemia, which is the leading cause of fatigue that debilitates day-to-day quality of life.  The oral ferrous iron preparations are often poorly tolerated, leaving intravenous iron infusions as the preferred option.  However these require significant additional patient time and healthcare resources, hence there is an urgent need for a more convenient solution which we anticipate ST10 may deliver."

Shield Founder and Chief Executive Officer, Carl Sterritt, added:

"We are very grateful to the patients for their commitment, as well as the investigators and their research staff for their hard work and considerable skill that has made this study possible.  The completion of recruitment into this pivotal trial is an important step in bringing orally dosed ST10 to market as an effective way of correcting anaemia in patients who cannot tolerate oral ferrous iron therapy and so have to rely on the higher risk option of invasive and resource-consuming intravenous administration of iron."

About Shield Therapeutics

Shield Therapeutics (http://www.shieldtherapeutics.com), founded in 2008, is an independent specialty pharmaceutical company focused on the development and commercialisation of late-stage, mineral-derived hospital pharmaceuticals which address areas of high unmet medical need.  Shield is currently conducting pivotal Phase 3 studies of its lead asset, ST10, for the treatment of iron deficiency anaemia associated with inflammatory bowel disease and is soon to commence a Phase 3 study of ST10 for the treatment of iron deficiency anaemia in patients with chronic kidney disease.

For more information about Shield Therapeutics, please contact:
M:Communications
Mary-Jane Elliott / Sarah Macleod/ Hollie Vile
Tel +44(0)20-7920-2330
Email: shieldtherapeutics@mcomgroup.com



'/>"/>
SOURCE Shield Therapeutics
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. ASSA ABLOY Door Group Announces RF Shielding Openings
2. Blue Cross Blue Shield Texas Launches "Be Covered Texas" Campaign to Raise Awareness of Individual Health Insurance Enrollment Options
3. Radiation Detection, Monitoring & Safety Market (Geiger Counter, Ionization Chamber, Scintillator, Terahertz detector, Dosimeter, Environment Monitor, Shield, Lead Apron, Eyewear & Glove) - Competitive Analysis & Global Forecasts to 2017
4. Healthcare Fraud Shield Now Offers SIU Services
5. FDA Grants Soligenix Fast Track Designation for OrbeShield(TM) for the Reduction of Mortality Associated with Gastrointestinal Acute Radiation Syndrome (GI ARS)
6. BI-LO Offers Health Giveaways With Flu Vaccinations, Encourages Community To Shield Their Health This Flu Season
7. Shield HealthCare Announces 12th Annual Caregiver Story Contest
8. Wellness Center USA, Inc. Completes Psoria-Shield Inc. Acquisition
9. Healthcare Expense Management Leader Patientco Receives $3.75M in funding led by BlueCross BlueShield Venture Partners and Sandbox Industries
10. Wellness Center USA Inc. Signs Agreement to Acquire Psoria-Shield Inc.
11. Blue Cross Blue Shield of Michigan and Blue Care Network support the Drug Enforcement Administrations Nationwide Prescription "Drug Take-Back Day"
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:6/23/2016)... -- MedSource announced today that it has selected Datatrial,s ... choice.  This latest decision demonstrates MedSource,s commitment to ... by offering a state-of-the-art electronic data capture (EDC) ... the EDC platform of choice in exchange for ... long been a preferred EDC platform by our ...
(Date:6/23/2016)... -- Any dentist who has made an implant supported denture ... of them do not even offer this as a viable ... costs involved. And those who ARE able to offer that ... cost that the majority of today,s patients would not be ... , founder of Dental Evolutions Inc. and inventor of Implanova ...
(Date:6/23/2016)... June 23, 2016  In a startling report released today, ... residents by lacking a comprehensive, proven plan to eliminate prescription opioid ... ranking of how states are tackling the worst drug crisis in ... states – Kentucky , New Mexico ... . Of the 28 failing states, three – ...
Breaking Medicine Technology:
(Date:6/25/2016)... ... June 25, 2016 , ... ... issues and applications at AcademyHealth’s Annual Research Meeting June 26-28, 2016, at the ... several important health care topics including advance care planning, healthcare costs and patient ...
(Date:6/25/2016)... ... June 25, 2016 , ... As a lifelong Southern Californian, Dr. Omkar Marathe ... from the David Geffen School of Medicine at UCLA. He trained in Internal Medicine ... his fellowship in hematology/oncology at the UCLA-Olive View-Cedars Sinai program where he had the ...
(Date:6/24/2016)... ... ... Those who have experienced traumatic events may suffer from a complex set of ... or alcohol abuse, as a coping mechanism. To avoid this pain and suffering, Serenity ... event. , Trauma sufferers tend to feel a range of emotions, from depression, guilt, ...
(Date:6/24/2016)... (PRWEB) , ... June 24, 2016 , ... ... now offering micro-osteoperforation for accelerated orthodontic treatment. Dr. Cheng has extensive experience with ... Damon brackets , AcceleDent, and accelerated osteogenic orthodontics. , Micro-osteoperforation is a ...
(Date:6/24/2016)... ... June 24, 2016 , ... The Haute Beauty Network, ... M. Weintraub as a prominent plastic surgeon and the network’s newest partner. ... the most handsome men, look naturally attractive. Plastic surgery should be invisible.” He ...
Breaking Medicine News(10 mins):